Selegiline for Smoking Cessation - 1

PHASE2CompletedINTERVENTIONAL
Enrollment

246

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

January 31, 2009

Conditions
Nicotine Dependence
Interventions
DRUG

Selegiline Transdermal Patch

Selegiline cm(2) via transdermal system

DRUG

Placebo

Matching placebo via transdermal system

BEHAVIORAL

Smoking Cessation Counseling

Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks

Trial Locations (4)

20745

Department of Public & Community Health, College Park

45237

Tri-State Tobacco and Alcohol Research Center, Cincinnati

53233

Center For Tobacco Research and Intervention, Milwaukee

08901

Robert Wood Johnson Med School-Tobacco Dep Program, New Brunswick

All Listed Sponsors
collaborator

VA Office of Research and Development

FED

lead

National Institute on Drug Abuse (NIDA)

NIH

NCT00439413 - Selegiline for Smoking Cessation - 1 | Biotech Hunter | Biotech Hunter